Mark Froimson insider trades
Open-market stock purchases and sales by Mark Froimson, Director at Pacira BioSciences, Inc, from SEC Form 4 filings since Jun 14, 2017.
Track record: 50% of 2 scored buys are up 5% or more since purchase, averaging +29%.
Companies traded
- PCRX Pacira BioSciences, Inc: 2 buys, 3 sales, last Jun 10, 2026